Could Agenus Inc. (AGEN) See a Reversal After Breaking Its 52 Week Low?

June 14, 2018 - By Kristen Paramore

Agenus Inc. (NASDAQ:AGEN) Logo

Investors sentiment increased to 1.46 in Q1 2018. Its up 0.20, from 1.26 in 2017Q4. It is positive, as 11 investors sold Agenus Inc. shares while 24 reduced holdings. 20 funds opened positions while 31 raised stakes. 46.47 million shares or 27.93% more from 36.32 million shares in 2017Q4 were reported.
31,000 are held by Badgley Phelps And Bell Inc. Swiss Bank & Trust holds 156,500 shares or 0% of its portfolio. Pathstone Family Office Ltd Liability stated it has 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Blair William Il reported 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Moreover, Bnp Paribas Arbitrage Sa has 0% invested in Agenus Inc. (NASDAQ:AGEN). Oracle Invest Mngmt Incorporated invested in 1.77% or 1.55 million shares. Price T Rowe Assoc Md has 0% invested in Agenus Inc. (NASDAQ:AGEN). Fmr Limited Co holds 0% or 863,541 shares in its portfolio. State Board Of Administration Of Florida Retirement Sys stated it has 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Bluecrest Capital Mngmt holds 10,341 shares. Vident Advisory Ltd Liability Corp owns 484,930 shares. Citadel Advisors Limited Liability Com accumulated 108,363 shares. Stifel Financial has 0% invested in Agenus Inc. (NASDAQ:AGEN) for 10,066 shares. Tiaa Cref Inv Ltd Limited Liability Company reported 0% in Agenus Inc. (NASDAQ:AGEN). Manufacturers Life Insurance The, a Ontario – Canada-based fund reported 59,786 shares.

The stock of Agenus Inc. (NASDAQ:AGEN) hit a new 52-week low and has $2.55 target or 9.00 % below today’s $2.80 share price. The 9 months bearish chart indicates high risk for the $291.20M company. The 1-year low was reported on Jun, 14 by Barchart.com. If the $2.55 price target is reached, the company will be worth $26.21M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 1.75% or $0.05 during the last trading session, reaching $2.8. About 1.46M shares traded or 0.54% up from the average. Agenus Inc. (NASDAQ:AGEN) has declined 0.29% since June 14, 2017 and is downtrending. It has underperformed by 12.86% the S&P500.

Analysts await Agenus Inc. (NASDAQ:AGEN) to report earnings on August, 2. They expect $-0.43 EPS, down 34.38 % or $0.11 from last year’s $-0.32 per share. After $-0.42 actual EPS reported by Agenus Inc. for the previous quarter, Wall Street now forecasts 2.38 % negative EPS growth.

Another recent and important Agenus Inc. (NASDAQ:AGEN) news was published by Seekingalpha.com which published an article titled: “Agenus: Buy, Sell Or Hold?” on May 18, 2018.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company has market cap of $291.20 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: